https://www.nytimes.com/2020/11/18/health/pfizer-covid-vaccine.html?action=click&module=Spotlight&pgtype=Homepage
The drug maker Pfizer said on Wednesday
that its coronavirus vaccine was 95 percent effective and had no serious
side effects — the first set of complete results from a late-stage
vaccine trial as Covid-19 cases skyrocket around the globe.
The
data showed that the vaccine prevented mild and severe forms of
Covid-19, the company said. And it was 94 percent effective in older
adults, who are more vulnerable to developing severe Covid-19 and who do
not respond strongly to some types of vaccines.
Pfizer,
which developed the vaccine with its partner BioNTech, said the
companies planned to apply to the Food and Drug Administration for
emergency authorization “within days,” raising hopes that a working
vaccine could soon become a reality.
If the F.D.A. authorizes the two-dose
vaccine, Pfizer has said that it could have up to 50 million doses
available by the end of the year, and up to 1.3 billion by the end of
next year.
However, only about half of its supply
will go to the United States this year, or enough for about 12.5 million
people — a sliver of the American population of 330 million. Americans
will receive the vaccine for free, under a $1.95 billion deal the
federal government reached with Pfizer for 100 million doses.